Microsoft launches wearable fitness monitor; NuVasive hits 52-week high following earnings report;

@FierceMedDev: ICYMI: Diagnostic companies homing on on rapid mobile tests to quell Ebola outbreak. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Medtronic discloses new corporate structure upon Covidien deal close. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific set to face first federal trials over transvaginal mesh products. Reuters article | Follow @EmilyWFierce

> Tech companies continue to venture into med tech, especially the wearable devices arena. Microsoft ($MSFT) launched Microsoft Band, a wrist-worn device with sensors that monitor pulse rate, calories burned and sleep quality. Story

> On Friday, shares in spinal implant device company NuVasive reached a 52-week high, as the company reported a loss of $1.8 million on sales of $189.9 million, $10 million higher than expected. News

> Sorin Group, a cardiovascular diseases device company, enrolled 1,039 patients with severe heart failure in a study testing the safety of the SonR cardiac resynchronization therapy (CRT) optimization system, which features a unique hemodynamic sensor. Release

Biotech News

@FierceBiotech: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies. News | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers beefs up fibrosis pipeline with $444M option deal. Report | Follow @JohnCFierce

@DamianFierce: $BMY gets into IPF with Galecto (and Magnus Persson, its fantastically named chairman) in a deal worth up to $444M. Release | Follow @DamianFierce

@EmilyMFierce: The planet's deadliest infectious diseases, by country. More via Salon | Follow @EmilyMFierce

> Geron shares rocket up after FDA takes the cuffs off its lead drug. Story

> $6B Covance buyout puts LabCorp in the CRO biz. Report

> Takeda drops a $750M schizophrenia drug pact with Intra-Cellular. Item

Pharma News

@FiercePharma: Tops this weekend: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts. Article | Follow @FiercePharma

@EricPFierce: The revamp continues at Takeda, as does its financial struggles. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts Gilead. Story | Follow @CarlyHFierce

> Bristol-Myers' 91-country hep C access plan still draws fire from price critics. More

> AstraZeneca seals the deal for Almirall's respiratory meds. Article

CRO News

> PRA raises the stakes, eyeing $400M in a blockbuster IPO. More

> CRO Paragon raises $13M to expand its footprint. Story

> LabCorp is buying Covance for $5.6B to cut in on the CRO boom. News

> Timely deals boost Charles River's balance sheet. Story

> Quintiles posts another $1B quarter and dials up its expectations. Report

Biotech IT News

> Venter makes new hires at Synthetic Genomics and Human Longevity. Item

> Cleveland Clinic teams with IBM to use Watson in genomics cancer research. Report

> Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs. More

> Novo Nordisk pushes back date of IT IPO decision to 2015. Story

> Boehringer picks IDBS system in consolidation of ELN. Article

Animal Health News

> IDEXX follows positive earnings with acquisition of Animana. Item

> Advaxis sees encouraging results for immuno-oncology treatment in dogs with bone cancer. Report

> Analysts to Heska: Why has strong performance been overlooked? Article

> Jaguar Animal Health trims IPO target number by 26%. More

> Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes. Story

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.